about
The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactionsPim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplicationIdentification and characterization of the major alternative promoter regulating Bcrp1/Abcg2 expression in the mouse intestineThe novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2Bcrp1 transcription in mouse testis is controlled by a promoter upstream of a novel first exon (E1U) regulated by steroidogenic factor-1
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-7435-1477
@en
name
Karthika Natarajan
@ast
Karthika Natarajan
@en
Karthika Natarajan
@es
Karthika Natarajan
@nl
type
label
Karthika Natarajan
@ast
Karthika Natarajan
@en
Karthika Natarajan
@es
Karthika Natarajan
@nl
prefLabel
Karthika Natarajan
@ast
Karthika Natarajan
@en
Karthika Natarajan
@es
Karthika Natarajan
@nl
P106
P1153
8310099300
P31
P496
0000-0001-7435-1477